Selected research
Industry Research
Transmucosal Drug Delivery Industry Research Report 2026
Market perspective
The global Transmucosal Drug Delivery market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Transmucosal Drug Delivery market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Transmucosal Drug Delivery market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Transmucosal Drug Delivery market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Transmucosal Drug Delivery include TEVA Pharmaceutical Industries Ltd., Mylan, Inc., Zosano Pharma, tesa Labtec GmbH, Tapemark, Pantec Biosolutions AG, Noven Pharmaceuticals, Inc., Nitto Denko Corporation and Nemaura Pharma Ltd, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Transmucosal Drug Delivery market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Transmucosal Drug Delivery.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Transmucosal Drug Delivery Market by Company
TEVA Pharmaceutical Industries Ltd.
Mylan, Inc.
Zosano Pharma
tesa Labtec GmbH
Tapemark
Pantec Biosolutions AG
Noven Pharmaceuticals, Inc.
Nitto Denko Corporation
Nemaura Pharma Ltd
MedPharm LTD
Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
Inovio Pharmaceuticals, Inc.
Generex Biotechnology Corporation
DURECT Corporation
Corium International, Inc
Aveva Drug Delivery Systems
Apricus BioSciences, Inc
Antares Pharma, Inc.
ALZA Corporation
Acrux Limited
3M Pharmaceuticals
Transmucosal Drug Delivery Segment by Type
Passive Transdermal Drug Delivery
Active Transdermal Drug Delivery
Transmucosal Drug Delivery Segment by Application
Hospital
Clinic
Others
Transmucosal Drug Delivery Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transmucosal Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transmucosal Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transmucosal Drug Delivery.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Transmucosal Drug Delivery companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Passive Transdermal Drug Delivery
- Active Transdermal Drug Delivery
Applications
- Hospital
- Clinic
- Others
Companies covered
- TEVA Pharmaceutical Industries Ltd.
- Mylan, Inc.
- Zosano Pharma
- tesa Labtec GmbH
- Tapemark
- Pantec Biosolutions AG
- Noven Pharmaceuticals, Inc.
- Nitto Denko Corporation
- Nemaura Pharma Ltd
- MedPharm LTD
- Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
- Inovio Pharmaceuticals, Inc.
- Generex Biotechnology Corporation
- DURECT Corporation
- Corium International, Inc
- Aveva Drug Delivery Systems
- Apricus BioSciences, Inc
- Antares Pharma, Inc.
- ALZA Corporation
- Acrux Limited
- 3M Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Transmucosal Drug Delivery by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Passive Transdermal Drug Delivery
- 2.2.3 Active Transdermal Drug Delivery
- 2.3 Transmucosal Drug Delivery by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Transmucosal Drug Delivery Breakdown Data by Type
- 3.1 Global Transmucosal Drug Delivery Historic Market Size by Type (2021-2026)
- 3.2 Global Transmucosal Drug Delivery Forecasted Market Size by Type (2027-2032)
4 Transmucosal Drug Delivery Breakdown Data by Application
- 4.1 Global Transmucosal Drug Delivery Historic Market Size by Application (2021-2026)
- 4.2 Global Transmucosal Drug Delivery Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Transmucosal Drug Delivery Market Perspective (2021-2032)
- 5.2 Global Transmucosal Drug Delivery Growth Trends by Region
- 5.2.1 Global Transmucosal Drug Delivery Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Transmucosal Drug Delivery Historic Market Size by Region (2021-2026)
- 5.2.3 Transmucosal Drug Delivery Forecasted Market Size by Region (2027-2032)
- 5.3 Transmucosal Drug Delivery Market Dynamics
- 5.3.1 Transmucosal Drug Delivery Industry Trends
- 5.3.2 Transmucosal Drug Delivery Market Drivers
- 5.3.3 Transmucosal Drug Delivery Market Challenges
- 5.3.4 Transmucosal Drug Delivery Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Transmucosal Drug Delivery Players by Revenue
- 6.1.1 Global Top Transmucosal Drug Delivery Players by Revenue (2021-2026)
- 6.1.2 Global Transmucosal Drug Delivery Revenue Market Share by Players (2021-2026)
- 6.2 Global Transmucosal Drug Delivery Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Transmucosal Drug Delivery Head Office and Area Served
- 6.4 Global Transmucosal Drug Delivery Players, Product Type & Application
- 6.5 Global Transmucosal Drug Delivery Manufacturers Established Date
- 6.6 Global Transmucosal Drug Delivery Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Transmucosal Drug Delivery Market Size (2021-2032)
- 7.2 North America Transmucosal Drug Delivery Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Transmucosal Drug Delivery Market Size by Country (2021-2026)
- 7.4 North America Transmucosal Drug Delivery Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Transmucosal Drug Delivery Market Size (2021-2032)
- 8.2 Europe Transmucosal Drug Delivery Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Transmucosal Drug Delivery Market Size by Country (2021-2026)
- 8.4 Europe Transmucosal Drug Delivery Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Transmucosal Drug Delivery Market Size (2021-2032)
- 9.2 Asia-Pacific Transmucosal Drug Delivery Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Transmucosal Drug Delivery Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Transmucosal Drug Delivery Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Transmucosal Drug Delivery Market Size (2021-2032)
- 10.2 South America Transmucosal Drug Delivery Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Transmucosal Drug Delivery Market Size by Country (2021-2026)
- 10.4 South America Transmucosal Drug Delivery Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Transmucosal Drug Delivery Market Size (2021-2032)
- 11.2 Middle East & Africa Transmucosal Drug Delivery Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Transmucosal Drug Delivery Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Transmucosal Drug Delivery Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 TEVA Pharmaceutical Industries Ltd.
- 12.1.1 TEVA Pharmaceutical Industries Ltd. Company Information
- 12.1.2 TEVA Pharmaceutical Industries Ltd. Business Overview
- 12.1.3 TEVA Pharmaceutical Industries Ltd. Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.1.4 TEVA Pharmaceutical Industries Ltd. Transmucosal Drug Delivery Product Portfolio
- 12.1.5 TEVA Pharmaceutical Industries Ltd. Recent Developments
- 12.2 Mylan, Inc.
- 12.2.1 Mylan, Inc. Company Information
- 12.2.2 Mylan, Inc. Business Overview
- 12.2.3 Mylan, Inc. Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.2.4 Mylan, Inc. Transmucosal Drug Delivery Product Portfolio
- 12.2.5 Mylan, Inc. Recent Developments
- 12.3 Zosano Pharma
- 12.3.1 Zosano Pharma Company Information
- 12.3.2 Zosano Pharma Business Overview
- 12.3.3 Zosano Pharma Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.3.4 Zosano Pharma Transmucosal Drug Delivery Product Portfolio
- 12.3.5 Zosano Pharma Recent Developments
- 12.4 tesa Labtec GmbH
- 12.4.1 tesa Labtec GmbH Company Information
- 12.4.2 tesa Labtec GmbH Business Overview
- 12.4.3 tesa Labtec GmbH Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.4.4 tesa Labtec GmbH Transmucosal Drug Delivery Product Portfolio
- 12.4.5 tesa Labtec GmbH Recent Developments
- 12.5 Tapemark
- 12.5.1 Tapemark Company Information
- 12.5.2 Tapemark Business Overview
- 12.5.3 Tapemark Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.5.4 Tapemark Transmucosal Drug Delivery Product Portfolio
- 12.5.5 Tapemark Recent Developments
- 12.6 Pantec Biosolutions AG
- 12.6.1 Pantec Biosolutions AG Company Information
- 12.6.2 Pantec Biosolutions AG Business Overview
- 12.6.3 Pantec Biosolutions AG Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.6.4 Pantec Biosolutions AG Transmucosal Drug Delivery Product Portfolio
- 12.6.5 Pantec Biosolutions AG Recent Developments
- 12.7 Noven Pharmaceuticals, Inc.
- 12.7.1 Noven Pharmaceuticals, Inc. Company Information
- 12.7.2 Noven Pharmaceuticals, Inc. Business Overview
- 12.7.3 Noven Pharmaceuticals, Inc. Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.7.4 Noven Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio
- 12.7.5 Noven Pharmaceuticals, Inc. Recent Developments
- 12.8 Nitto Denko Corporation
- 12.8.1 Nitto Denko Corporation Company Information
- 12.8.2 Nitto Denko Corporation Business Overview
- 12.8.3 Nitto Denko Corporation Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.8.4 Nitto Denko Corporation Transmucosal Drug Delivery Product Portfolio
- 12.8.5 Nitto Denko Corporation Recent Developments
- 12.9 Nemaura Pharma Ltd
- 12.9.1 Nemaura Pharma Ltd Company Information
- 12.9.2 Nemaura Pharma Ltd Business Overview
- 12.9.3 Nemaura Pharma Ltd Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.9.4 Nemaura Pharma Ltd Transmucosal Drug Delivery Product Portfolio
- 12.9.5 Nemaura Pharma Ltd Recent Developments
- 12.10 MedPharm LTD
- 12.10.1 MedPharm LTD Company Information
- 12.10.2 MedPharm LTD Business Overview
- 12.10.3 MedPharm LTD Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.10.4 MedPharm LTD Transmucosal Drug Delivery Product Portfolio
- 12.10.5 MedPharm LTD Recent Developments
- 12.11 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
- 12.11.1 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Company Information
- 12.11.2 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Business Overview
- 12.11.3 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.11.4 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Transmucosal Drug Delivery Product Portfolio
- 12.11.5 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Recent Developments
- 12.12 Inovio Pharmaceuticals, Inc.
- 12.12.1 Inovio Pharmaceuticals, Inc. Company Information
- 12.12.2 Inovio Pharmaceuticals, Inc. Business Overview
- 12.12.3 Inovio Pharmaceuticals, Inc. Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.12.4 Inovio Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio
- 12.12.5 Inovio Pharmaceuticals, Inc. Recent Developments
- 12.13 Generex Biotechnology Corporation
- 12.13.1 Generex Biotechnology Corporation Company Information
- 12.13.2 Generex Biotechnology Corporation Business Overview
- 12.13.3 Generex Biotechnology Corporation Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.13.4 Generex Biotechnology Corporation Transmucosal Drug Delivery Product Portfolio
- 12.13.5 Generex Biotechnology Corporation Recent Developments
- 12.14 DURECT Corporation
- 12.14.1 DURECT Corporation Company Information
- 12.14.2 DURECT Corporation Business Overview
- 12.14.3 DURECT Corporation Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.14.4 DURECT Corporation Transmucosal Drug Delivery Product Portfolio
- 12.14.5 DURECT Corporation Recent Developments
- 12.15 Corium International, Inc
- 12.15.1 Corium International, Inc Company Information
- 12.15.2 Corium International, Inc Business Overview
- 12.15.3 Corium International, Inc Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.15.4 Corium International, Inc Transmucosal Drug Delivery Product Portfolio
- 12.15.5 Corium International, Inc Recent Developments
- 12.16 Aveva Drug Delivery Systems
- 12.16.1 Aveva Drug Delivery Systems Company Information
- 12.16.2 Aveva Drug Delivery Systems Business Overview
- 12.16.3 Aveva Drug Delivery Systems Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.16.4 Aveva Drug Delivery Systems Transmucosal Drug Delivery Product Portfolio
- 12.16.5 Aveva Drug Delivery Systems Recent Developments
- 12.17 Apricus BioSciences, Inc
- 12.17.1 Apricus BioSciences, Inc Company Information
- 12.17.2 Apricus BioSciences, Inc Business Overview
- 12.17.3 Apricus BioSciences, Inc Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.17.4 Apricus BioSciences, Inc Transmucosal Drug Delivery Product Portfolio
- 12.17.5 Apricus BioSciences, Inc Recent Developments
- 12.18 Antares Pharma, Inc.
- 12.18.1 Antares Pharma, Inc. Company Information
- 12.18.2 Antares Pharma, Inc. Business Overview
- 12.18.3 Antares Pharma, Inc. Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.18.4 Antares Pharma, Inc. Transmucosal Drug Delivery Product Portfolio
- 12.18.5 Antares Pharma, Inc. Recent Developments
- 12.19 ALZA Corporation
- 12.19.1 ALZA Corporation Company Information
- 12.19.2 ALZA Corporation Business Overview
- 12.19.3 ALZA Corporation Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.19.4 ALZA Corporation Transmucosal Drug Delivery Product Portfolio
- 12.19.5 ALZA Corporation Recent Developments
- 12.20 Acrux Limited
- 12.20.1 Acrux Limited Company Information
- 12.20.2 Acrux Limited Business Overview
- 12.20.3 Acrux Limited Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.20.4 Acrux Limited Transmucosal Drug Delivery Product Portfolio
- 12.20.5 Acrux Limited Recent Developments
- 12.21 3M Pharmaceuticals
- 12.21.1 3M Pharmaceuticals Company Information
- 12.21.2 3M Pharmaceuticals Business Overview
- 12.21.3 3M Pharmaceuticals Revenue in Transmucosal Drug Delivery Business (2021-2026)
- 12.21.4 3M Pharmaceuticals Transmucosal Drug Delivery Product Portfolio
- 12.21.5 3M Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst